Literature DB >> 287454

Ocular side effects with 5-fluorouracil.

N Christophidis, F J Vajda, I Lucas, W J Louis.   

Abstract

The concentrations of 5-fluorouracil in tears and plasma were studied in eight patients receiving the drug for carcinoma of the colon. The drug was measured by a gas liquid chromatographic method and found to be present only in the tears of patients with excessive lacrimation. In three patients with watery eyes the peak concentration in tears (16-23.8 micrograms/ml) occurred 15 minutes after IV administration and this corresponded with the end of the distribution (alpha) phase in the plasma when the plasma levels ranged from 18-26 micrograms/ml. In five patients without eye symptoms the drug was undetectable in the lacrimal fluid even though they had similar plasma levels (15-25 micrograms/ml) of 5-fluorouracil. The volumes of distribution and plasma clearance rates were similar in the two groups [being 0.2-0.52 (mean = 0.33) 1/kg and 612-978 (mean = 850) ml/min respectively in patients with excessive lacrimation and 0.13-0.79 (mean = 0.36) 1/kg and 435-1138 (mean = 831) ml/min respectively in the five patients without symptoms.]. It appears that 5-fluorouracil produces irritation of the lacrimal apparatus in about 30% of patients on the drug and in association with this appears in the tears where it may be responsible for the reported irritation and fibrosis of the tear duct.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 287454     DOI: 10.1111/j.1445-5994.1979.tb04317.x

Source DB:  PubMed          Journal:  Aust N Z J Med        ISSN: 0004-8291


  12 in total

Review 1.  Antineoplastic drugs in 1990. A review (Part II).

Authors:  D J Black; R B Livingston
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

2.  5-Fluorouracil and ocular toxicity.

Authors:  J E Forbes; D J Brazier; M Spittle
Journal:  Br J Ophthalmol       Date:  1993-07       Impact factor: 4.638

3.  Iris crystals and uveitis.

Authors:  P I Murray
Journal:  Br J Ophthalmol       Date:  1993-07       Impact factor: 4.638

4.  Fractured laser fibreoptic cord.

Authors:  J Singh; K Swa
Journal:  Br J Ophthalmol       Date:  1993-07       Impact factor: 4.638

5.  Dacryoendoscopic observation and incidence of canalicular obstruction/stenosis associated with S-1, an oral anticancer drug.

Authors:  Tsugihisa Sasaki; Hiroaki Miyashita; Tamon Miyanaga; Katsushi Yamamoto; Kazuhisa Sugiyama
Journal:  Jpn J Ophthalmol       Date:  2012-03-13       Impact factor: 2.447

Review 6.  Supportive cryotherapy: a review from head to toe.

Authors:  Kunal C Kadakia; Shaina A Rozell; Anish A Butala; Charles L Loprinzi
Journal:  J Pain Symptom Manage       Date:  2013-11-07       Impact factor: 3.612

7.  Determination of 5-fluorouracil and tegafur in tear fluid of patients treated with oral fluoropyrimidine anticancer agent, S-1.

Authors:  Yoko Akune; Masakazu Yamada; Chika Shigeyasu
Journal:  Jpn J Ophthalmol       Date:  2018-06-21       Impact factor: 2.447

8.  Predictive factors for ocular complications caused by anticancer drug S-1.

Authors:  Rika Yamada; Chie Sotozono; Takahiro Nakamura; Akihiro Nishida; Shinya Nakanishi; Masaki Hirabatake; Akihito Tsuji; Yasuo Kurimoto
Journal:  Jpn J Ophthalmol       Date:  2016-02-03       Impact factor: 2.447

9.  Ocular surface and tear film abnormalities in women under adjuvant chemotherapy for breast cancer with the 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) regimen.

Authors:  A Karamitsos; V Kokkas; A Goulas; P Paraskevopoulos; K Gougoulias; V Karampatakis; K Boboridis
Journal:  Hippokratia       Date:  2013-04       Impact factor: 0.471

10.  Noninvasive direct detection of ocular mucositis by in vivo confocal microscopy in patients treated with S-1.

Authors:  Tai-ichiro Chikama; Norihisa Takahashi; Makiko Wakuta; Teruo Nishida
Journal:  Mol Vis       Date:  2009-12-26       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.